Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pancreatic Cancer

Pancreatic Cancer

21 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pancreatic Cancer

389 trials tracked for Pancreatic Cancer: 43 in phase 3 or 4 and 19 with published results. The most-cited published study has 444 citations.

389Trials tracked
43Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 9 Phase 3 34 Phase 2 256 Phase 1 36 Other / NA 54
  1. Phase 3 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Completed · 444 cited
  2. Phase 3 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed · 235 cited
  3. Phase 3 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Completed · 233 cited
  4. Phase 3 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed · 191 cited
  5. Phase 3 Cancer Associated Thrombosis and Isoquercetin (CATIQ) Completed · 172 cited
  6. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
Show 44 more trials
  1. Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 135 cited
  2. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 130 cited
  3. Phase 3 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? Completed · 127 cited
  4. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  5. Phase 3 Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer Completed · 110 cited
  6. Phase 3 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Completed · 99 cited
  7. Phase 3 Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas Completed · 87 cited
  8. Phase 4 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed · 63 cited
  9. Phase 3 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Completed · 56 cited
  10. Phase 3 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Completed · 41 cited
  11. Phase 3 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma Completed · 35 cited
  12. Phase 4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed · 30 cited
  13. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  14. Phase 4 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed
  15. Phase 4 Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients Completed
  16. Phase 4 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed
  17. Phase 4 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed
  18. Phase 4 Etomidate vs. Midazolam for Sedation During ERCP Completed
  19. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  20. Phase 3 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Completed
  21. Phase 3 Pentoxifylline Treatment in Acute Pancreatitis (AP) Completed
  22. Phase 3 Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies Completed
  23. Phase 3 Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Completed
  24. Phase 3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed
  25. Phase 3 Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Completed
  26. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  27. Phase 3 Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs Completed
  28. Phase 3 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer Completed
  29. Phase 3 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection Completed
  30. Phase 3 Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess Completed
  31. Phase 3 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed
  32. Phase 3 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed
  33. Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed
  34. Phase 3 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Completed
  35. Phase 3 Standardization of Surgery on the Pancreatic Cancer Completed
  36. Phase 3 A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer Completed
  37. Phase 3 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer Completed
  38. Phase 2 Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas Completed
  39. Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Completed
  40. Phase 2 Azacitidine and Pembrolizumab in Pancreatic Cancer Completed
  41. Phase 2 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Completed
  42. Phase 2 RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer Completed
  43. Phase 2 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Completed
  44. Phase 2 LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy Completed

Showing the 50 most-cited and recently-updated of 389 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pancreatic Cancer: what the trials found

The addition of TTFields to the combination of Gemcitabine and Nab-paclitaxel significantly improved overall survival compared to chemotherapy alone (16.20 vs 14.16 months, p=0.039) 1. However, this combination did not show statistically significant improvements in progression-free survival or local progression-free survival compared to the control group 1.

Other established interventions include Gemcitabine [2, 15], Dalteparin 19, and sunitinib; the latter showed objective response rates of 21.3% to 28.9% by investigator assessment and 52.5% to 55.6% by independent radiological review 20.

Additional established interventions include arginine/lysine, which demonstrated specific changes in serum potassium levels and blood gas parameters over 24 hours 21, and Superparamagnetic Iron Oxide Magnetic Resonance Imaging 22.

Recent results — preliminary, needs further review

  • Paricalcitol (Zemplar) was associated with a significant reduction in serum levels of Carbohydrate Antigen 19-9 (CA19-9) (p=0.001) 5.
  • Acupuncture therapy was evaluated for managing chemotherapy-induced peripheral neuropathy (CIPN) and related symptoms such as pain, fatigue, nausea, and anxiety 16.
  • Paclitaxel Protein Bound (Abraxane) showed a statistically significant improvement in R0 resectability rates (p=0.017), though it did not significantly impact CA 19-9 normalization or pathologic complete response rate 7.
  • Vemurafenib was associated with specific percentage changes in plasma levels of Phospho-ERK and Phospho-AKT 11.

For the clinician treating this condition

  • TTFields combined with Gemcitabine and Nab-paclitaxel provides a statistically significant survival benefit over chemotherapy alone, though it does not currently show a significant impact on progression-free metrics.
  • Paricalcitol is associated with a significant reduction in CA19-9 levels.
  • Abraxane showed a significant improvement in R0 resectability rates despite non-significant results for other markers like pathologic complete response.

AI synthesis of 9 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months
Oncology RCT
Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months Trial shows daraxonrasib improves survival for pancreatic cancer patients
This Phase 3 randomized trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma found daraxonrasib signifi…
A Phase 3 trial found that daraxonrasib significantly extended survival times for patients with specific types of metastatic pancreatic canc…
Jul 26, 2026
Mistletoe extract plus standard treatment shows no quality of life benefit in advanced pancreatic cancer
Palliative Care RCT
Mistletoe extract plus standard treatment shows no quality of life benefit in advanced pancreatic cancer Trial shows mistletoe extract does not improve pancreatic cancer care
This Phase III randomized controlled trial evaluated mistletoe extract combined with standard care in 290 patients with advanced pancreatic …
A large trial found that adding mistletoe extract to standard treatment did not improve quality of life or weight for patients with advanced…
Jul 25, 2026
High red meat consumption increases pancreatic cancer risk by 16% in large population meta-analysis
Oncology Meta-analysis
High red meat consumption increases pancreatic cancer risk by 16% in large population meta-analysis High Red Meat Consumption Linked to Increased Pancreatic Cancer Risk
This meta-analysis of 1,959,527 participants found that the highest levels of red meat consumption are associated with a 16% increased risk …
New data suggests that eating more red meat may increase your risk of pancreatic cancer, while no link was found for processed meats.
Frontiers Jul 16, 2026
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer
Oncology RCT
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer Trial tests two chemo combos for older pancreatic cancer patients
This Phase III randomized controlled trial is evaluating neoadjuvant gemcitabine plus nab-paclitaxel compared to gemcitabine plus S-1 in 400…
A new trial compares two chemotherapy combinations for older adults with resectable pancreatic cancer.
Jul 12, 2026
Reverse-bevel ProCore FNB provides diagnostic yield comparable to standard FNA for pancreatic mass lesions
Oncology Meta-analysis
Reverse-bevel ProCore FNB provides diagnostic yield comparable to standard FNA for pancreatic mass lesions New needle technique may reduce passes for pancreatic cancer biopsy
This meta-analysis of 412 patients with solid pancreatic mass lesions found that reverse-bevel ProCore fine needle biopsy (FNB) yields resul…
A new needle design for pancreatic cancer biopsies provides similar results to standard methods but requires fewer passes into the tissue.
Jul 8, 2026
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
Nutrition & Obesity Medicine Sys. Review
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types Sugar sweetened drinks may increase risk of several cancer types
This meta-analysis of 51 cohort studies evaluates the link between sugar sweetened beverages (SSBs), artificially sweetened beverages (ASBs)…
New research suggests a link between sugar-sweetened beverages and an increased risk of certain cancers, including pancreatic and colorectal…
medRxiv Jul 7, 2026
Meta-analysis Evaluating Occupational Hexavalent Chromium Exposure and Specific Malignancy Risks
Oncology Meta-analysis
Meta-analysis Evaluating Occupational Hexavalent Chromium Exposure and Specific Malignancy Risks Occupational Chromium Exposure Linked to Bladder Cancer Mortality
A meta-analysis of 29 publications examined how occupational hexavalent chromium exposure impacts various cancer types in human populations.
A review of 29 publications found that while most cancers showed no link, bladder cancer mortality was associated with hexavalent chromium e…
Jun 28, 2026
Cadmium exposure increases pancreatic cancer risk with an RR of 1.69 across meta-analyzed data
Oncology Meta-analysis
Cadmium exposure increases pancreatic cancer risk with an RR of 1.69 across meta-analyzed data Cadmium exposure linked to 69% higher pancreatic cancer risk
This meta-analysis evaluates the link between cadmium exposure from various sources and pancreatic cancer incidence. The analysis found that…
People exposed to cadmium may face a 69% higher risk of pancreatic cancer, a new analysis finds.
Jun 25, 2026
Intratumoral microbiome linked to survival and chemotherapy resistance in pancreatic cancer
Oncology Sys. Review
Intratumoral microbiome linked to survival and chemotherapy resistance in pancreatic cancer Tumor Bacteria Linked to Pancreatic Cancer Survival
This systematic review synthesizes evidence that the intratumoral microbiome in pancreatic cancer is mainly composed of Proteobacteria and F…
Bacteria inside pancreatic tumors may influence how long patients live and how well chemo works.
Frontiers Jun 19, 2026
Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer
Oncology Sys. Review
Combination strategies using DNA damage response inhibitors aim to overcome resistance in pancreatic cancer New combination strategies aim to treat pancreatic cancer more effectively
This systematic review evaluates DNA damage response (DDR) inhibitors, including monotherapy and combination regimens, for pancreatic cancer…
Combining different drugs could help overcome treatment resistance and reach more patients with pancreatic cancer.
Frontiers Jun 16, 2026
Pancreatic cancer involves multilayered mechanisms from environment to immune escape
Diabetes & Endocrinology Sys. Review
Pancreatic cancer involves multilayered mechanisms from environment to immune escape Review reveals complex causes of pancreatic cancer
This narrative review synthesizes the multilayered mechanisms of pancreatic cancer, including environmental exposure, genetic susceptibility…
Pancreatic cancer arises from a mix of genetics, lifestyle, and inflammation, review finds.
Frontiers Jun 13, 2026
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Oncology Meta-analysis
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
Frontiers Jun 11, 2026

Questions about Pancreatic Cancer

Is there a link between Periodontal Disease and pancreatic cancer in older adults?

Yes, research suggests periodontal disease is linked to a higher risk of pancreatic cancer in older adults, possibly due to chronic inflammation and oral bacteria.

Full answer →
Does the protein OTUD7B promote the growth of tumors in pancreatic cancer?

Yes, OTUD7B promotes pancreatic cancer growth by stabilizing oncoproteins and activating signaling pathways like Notch and EGFR/MAPK.

Full answer →
Is EGCG a potential treatment for digestive system diseases like pancreatic cancer?

EGCG shows promise against pancreatic cancer in lab and animal studies, but human trials are lacking, so it is not yet a proven treatment.

Full answer →
What environmental factors and genetic risks contribute to the development of pancreatic cancer?

Pancreatic cancer risk comes from modifiable factors like smoking, obesity, and heavy drinking, plus inherited mutations in genes such as BRCA1/2 and PALB2.

Full answer →
Can DNA damage response inhibitors overcome drug resistance in pancreatic cancer?

Yes, DNA damage response inhibitors can help overcome drug resistance in pancreatic cancer, especially when combined with other therapies, but single-agent use has limitations.

Full answer →
See all 5 questions about Pancreatic Cancer →

All Pancreatic Cancer Articles